(NASDAQ: EVAX) Evaxion A's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.98%.
Evaxion A's earnings in 2026 is -$7,707,000.On average, 6 Wall Street analysts forecast EVAX's earnings for 2026 to be -$495,533,881, with the lowest EVAX earnings forecast at -$772,387,322, and the highest EVAX earnings forecast at -$17,514,452. On average, 6 Wall Street analysts forecast EVAX's earnings for 2027 to be -$350,914,551, with the lowest EVAX earnings forecast at -$772,387,322, and the highest EVAX earnings forecast at $48,164,742.
In 2028, EVAX is forecast to generate -$175,811,735 in earnings, with the lowest earnings forecast at -$510,838,176 and the highest earnings forecast at $17,514,452.